NASDAQ
0.26USD
-0.02 (-7.05%)
We have scored 3 news catalysts on Context Therapeutics Inc. (CNTX) over the past 12 months. The biggest single-day move next to one of them came Oct 15, 2026, when CNTX closed −7.1%: “New Strong Sell Stocks for October 15th”. Coverage across the window leans mixed (average ticker sentiment +0.00). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
23.5M
P/E
—
EPS
—
Beta
1.72
52W range
0.25-3.62
Day range
0.25–0.27
Open
0.27
Prev close
0.28
Volume
960.6K
Avg volume
2.3M
Dividend
0.00
IPO
2021-10-20
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Context Therapeutics Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CNTX: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
